With two FDA-cleared platforms available, the technology is drawing clinicians interested in reaping its near-term benefits while preparing for its future impact.
Excluding IPOs, the funding environment for private venture-backed financing Dx deals in the US and Europe was remarkably similar in 2018 to 2017, according to Silicon Valley Bank.
In developing the new tools, Google trained artificial intelligence algorithms to aid pathologists in making breast and prostate cancer diagnoses.
Google researchers said their technology was able to detect 89 percent of tumors compared to 73 percent for pathologists analyzing slides.
Mobile apps could one day transform the way diseases are diagnosed, but concerns have been raised about their accuracy and safety.